Cargando…

Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis

OBJECTIVE: Infusion reaction is a major adverse event in patients with rheumatoid arthritis (RA) treated with infliximab. The possible factors including Fcγ receptor (FcγR) polymorphism associated with the development of infusion reactions in patients with RA receiving infliximab were prospectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okuyama, Ayumi, Nagasawa, Hayato, Suzuki, Katsuya, Kameda, Hideto, Kondo, Harumi, Amano, Kouichi, Takeuchi, Tsutomu
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Group 2010
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015102/ https://www.ncbi.nlm.nih.gov/pubmed/20980704 http://dx.doi.org/10.1136/ard.2010.136283

Ejemplares similares

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
por: Tanaka, Yoshiya, et al.
Publicado: (2008)

Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study
por: Nakamura, Seiji, et al.
Publicado: (2016)

Fc Gamma Receptor IIIB (FcγRIIIB) Polymorphisms Are Associated with Clinical Malaria in Ghanaian Children
por: Adu, Bright, et al.
Publicado: (2012)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Overview of biotherapy in rheumatoid arthritis (RA)
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

What is the future of CCR5 antagonists in rheumatoid arthritis?
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)
por: Yamanaka, Hisashi, et al.
Publicado: (2010)

Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases
por: Kameda, Hideto, et al.
Publicado: (2007)

Infliximab-Related Infusion Reactions: Systematic Review
por: Lichtenstein, Lev, et al.
Publicado: (2015)

Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum
por: Yagi, Hirokazu, et al.
Publicado: (2018)

Incidence and baseline characteristics of relapse or exacerbation in patients with pulmonary sarcoidosis in Japan
por: Murata, Okinori, et al.
Publicado: (2021)

Immediate-type infliximab infusion reaction presenting as purpura
por: Soong, Laura, et al.
Publicado: (2018)

Fc Gamma Receptor CD64 Modulates the Inhibitory Activity of Infliximab
por: Wojtal, Kacper A., et al.
Publicado: (2012)

Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial
por: Bermel, Robert A., et al.
Publicado: (2021)

Site-Specific Glycosylation Mapping of Fc Gamma Receptor IIIb from Neutrophils of Individual Healthy Donors
por: Wojcik, Iwona, et al.
Publicado: (2020)

Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography–mass spectrometry
por: Lippold, Steffen, et al.
Publicado: (2021)

Predictors of infusion reactions during infliximab treatment in patients with arthritis
por: Kapetanovic, Meliha C, et al.
Publicado: (2006)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
por: Mir, Fazia A., et al.
Publicado: (2018)

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting
por: Checkley, L. Allyson, et al.
Publicado: (2018)

Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center
por: Park, Jiyeon Joy, et al.
Publicado: (2018)

A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis
por: Kameda, Hideto, et al.
Publicado: (2020)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Association of Fc gamma-receptors IIa, IIIa, and IIIb genetic polymorphism with susceptibility to chronic periodontitis in South Indian population
por: Hans, Veenu Madaan, et al.
Publicado: (2015)

Linear IgA dermatosis after infliximab infusion for ulcerative colitis
por: Bryant, Kelli D., et al.
Publicado: (2016)

Implementation and Evaluation of a Standard Operating Procedure for Pediatric Infliximab Infusions
por: Kelly, Maureen M., et al.
Publicado: (2019)

Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)
por: Izumi, Keisuke, et al.
Publicado: (2015)

Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)
por: Izumi, Keisuke, et al.
Publicado: (2016)

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
por: Alten, Rieke, et al.
Publicado: (2019)

Ionic liquids IIIB
por: Rogers, Robin D, et al.
Publicado: (2005)

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
por: Cohen, Stanley B., et al.
Publicado: (2018)

Successful Treatment of Tolosa-Hunt Syndrome after a Single Infusion of Infliximab
por: Halabi, Tarek, et al.
Publicado: (2018)

First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils
por: Weber, Felix, et al.
Publicado: (2018)

Association between Fcγ receptor IIA, IIIA and IIIB genetic polymorphisms and susceptibility to severe malaria anemia in children in western Kenya
por: Munde, Elly O., et al.
Publicado: (2017)

The Antibody Receptor Fc Gamma Receptor IIIb Induces Calcium Entry via Transient Receptor Potential Melastatin 2 in Human Neutrophils
por: Alemán, Omar Rafael, et al.
Publicado: (2021)

Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome
por: Yoshimoto, Keiko, et al.
Publicado: (2011)

Decreasing Door-to-Door Times for Infliximab Infusions in a Children's Hospital Observation Unit
por: Sandberg, Kelly C., et al.
Publicado: (2019)

A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol
por: Ong, Wan Chee, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i0bvkvo3lg193rqvp3f2f4j5pv